User profiles for Christopher Granger
Christopher B GrangerDuke University Medical Center Verified email at mc.duke.edu Cited by 277607 |
[HTML][HTML] Apixaban versus warfarin in patients with atrial fibrillation
CB Granger, JH Alexander, JJV McMurray… - … England Journal of …, 2011 - Mass Medical Soc
Background Vitamin K antagonists are highly effective in preventing stroke in patients with
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor …
atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor …
Predictors of hospital mortality in the global registry of acute coronary events
CB Granger, RJ Goldberg, O Dabbous… - Archives of internal …, 2003 - jamanetwork.com
Background Management of acute coronary syndromes (ACS) should be guided by an
estimate of patient risk. Objective To develop a simple model to assess the risk for in-hospital …
estimate of patient risk. Objective To develop a simple model to assess the risk for in-hospital …
2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart …
…, JC Fang, FM Fesmire, BA Franklin, CB Granger… - Journal of the American …, 2013 - jacc.org
1.1. Methodology and Evidence Review The recommendations listed in this document are,
whenever possible, evidence based. The current document constitutes a full revision and …
whenever possible, evidence based. The current document constitutes a full revision and …
[BOOK][B] Fundamentals of clinical trials
…, CD Furberg, DL DeMets, DM Reboussin, CB Granger - 2015 - Springer
The clinical trial is “the most definitive tool for evaluation of the applicability of clinical research.”
It represents “a key research activity with the potential to improve the quality of health …
It represents “a key research activity with the potential to improve the quality of health …
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Background Half of patients with chronic heart failure (CHF) have preserved left-ventricular
ejection fraction (LVEF), but few treatments have specifically been assessed in such patients. …
ejection fraction (LVEF), but few treatments have specifically been assessed in such patients. …
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College …
…, ME Field, GC Fonarow, AM Gillis, CB Granger… - Journal of the American …, 2018 - jacc.org
The recommendations listed in this clinical practice guideline are, whenever possible,
evidence-based. An initial extensive evidence review, which included literature derived from …
evidence-based. An initial extensive evidence review, which included literature derived from …
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo …
…, S Janmohamed, RB D'Agostino, CB Granger… - The Lancet, 2018 - thelancet.com
Background Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration
of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly …
of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly …
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the …
Background Angiotensin-converting-enzyme (ACE) inhibitors improve outcome of patients
with chronic heart failure (CHF). A substantial proportion of patients, however, experience no …
with chronic heart failure (CHF). A substantial proportion of patients, however, experience no …
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of …
The scope of this focused update is limited to addressing recommendations on duration of
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …
dual antiplatelet therapy (DAPT)(aspirin plus a P2Y12 inhibitor) in patients with coronary …
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM …
Background Angiotensin II type 1 receptor blockers have favourable effects on haemodynamic
measurements, neurohumoral activity, and left-ventricular remodelling when added to …
measurements, neurohumoral activity, and left-ventricular remodelling when added to …